Gemphire

GEMP NASDAQ
0.5600
-0.0058
-1.03%
盘后: 0.5563 -0.0037 -0.66% 17:15 08/16 EDT
开盘
0.5600
昨收
0.5658
最高
0.6000
最低
0.5500
成交量
7.28万
成交均量(3M)
26.06万
52周最高
2.650
52周最低
0.5208
换手率
0.49%
市值
832.86万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Gemphire GEMP股票价格,Gemphire股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.
展开 >

最近浏览

名称
价格
涨跌幅